These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24650011)

  • 21. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
    Gaballa MR; Besa EC
    Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes.
    Schmitt N; Jann JC; Altrock E; Flach J; Danner J; Uhlig S; Streuer A; Knaflic A; Riabov V; Xu Q; Mehralivand A; Palme I; Nowak V; Obländer J; Weimer N; Haselmann V; Jawhar A; Darwich A; Weis CA; Marx A; Steiner L; Jawhar M; Metzgeroth G; Boch T; Nolte F; Hofmann WK; Nowak D
    Leukemia; 2022 Jan; 36(1):236-247. PubMed ID: 34172896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunomodulating drugs in myelodysplastic syndromes.
    Adès L; Fenaux P
    Hematology Am Soc Hematol Educ Program; 2011; 2011():556-60. PubMed ID: 22160089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.
    Roth M; Will B; Simkin G; Narayanagari S; Barreyro L; Bartholdy B; Tamari R; Mitsiades CS; Verma A; Steidl U
    Blood; 2012 Jul; 120(2):386-94. PubMed ID: 22627766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.
    Jeong JY; Levine MS; Abayasekara N; Berliner N; Laubach J; Vanasse GJ
    J Hematol Oncol; 2015 Apr; 8():37. PubMed ID: 25886818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells.
    Shi M; Xu F; Yang X; Bai Y; Niu J; Drokow EK; Chen M; Chen Y; Sun K
    Cancer Manag Res; 2019; 11():8229-8238. PubMed ID: 31564981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
    Narayan R; Garcia JS; Percival ME; Berube C; Coutre S; Gotlib J; Greenberg P; Liedtke M; Hewitt R; Regan K; Williamson C; Doykan C; Cardone MH; McMillan A; Medeiros BC
    Leuk Lymphoma; 2016; 57(3):609-15. PubMed ID: 26374199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure.
    Duong VH; Al Ali N; Zhang L; Padron E; Sallman D; Lancet JE; List AF; Komrokji RS
    Leuk Lymphoma; 2020 Aug; 61(8):1901-1907. PubMed ID: 32306798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of lenalidomide in the treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.
    Matsuoka A; Tochigi A; Kishimoto M; Nakahara T; Kondo T; Tsujioka T; Tasaka T; Tohyama Y; Tohyama K
    Leukemia; 2010 Apr; 24(4):748-55. PubMed ID: 20130600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
    Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
    Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
    Fenaux P; Giagounidis A; Selleslag D; Beyne-Rauzy O; Mittelman M; Muus P; Nimer SD; Hellström-Lindberg E; Powell BL; Guerci-Bresler A; Sekeres MA; Deeg HJ; Del Cañizo C; Greenberg PL; Shammo JM; Skikne B; Yu X; List AF
    J Hematol Oncol; 2017 Jun; 10(1):131. PubMed ID: 28651604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
    Stahl M; Zeidan AM
    Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation.
    Di Buduo CA; Currao M; Pecci A; Kaplan DL; Balduini CL; Balduini A
    Haematologica; 2016 Dec; 101(12):1479-1488. PubMed ID: 27515246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation.
    Ferrajoli A; Talpaz M; Kurzrock R; Harris D; Van Q; Estey EH; Estrov Z
    Leuk Lymphoma; 1998 Jul; 30(3-4):279-92. PubMed ID: 9713960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
    Arcioni F; Roncadori A; Di Battista V; Tura S; Covezzoli A; Cundari S; Mecucci C;
    Eur J Haematol; 2018 Jul; 101(1):78-85. PubMed ID: 29569278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.
    Leitch HA; Buckstein R; Shamy A; Storring JM
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):162-92. PubMed ID: 22901762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.
    Feldman EJ; Seiter KP; Ahmed T; Baskind P; Arlin ZA
    Leukemia; 1996 Jan; 10(1):40-2. PubMed ID: 8558935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients.
    Chan AC; Neeson P; Leeansyah E; Tainton K; Quach H; Prince HM; Godfrey DI; Ritchie D; Berzins SP
    Leukemia; 2010 Mar; 24(3):592-600. PubMed ID: 20072154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.